Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to evaluate the immunogenicity of Avonex® (interferon
beta-1a) 30 mcg when administered subcutaneously (SC) to interferon-naïve participants with
relapsing multiple sclerosis. The secondary objective of this study was to evaluate the
safety and tolerability of Avonex® 30 mcg when administered SC to interferon-naïve subjects
with relapsing MS.